24May 2018

NOVEL THERAPEUTIC USE OF INSULIN AND VITAMIN E IN (NAFLD) USING FATTY LIVER INDUCED RATS.

  • Faculty of Biotechnology, Misr University for Science and Technology, Giza, Egypt.
  • R&D department, Heliopolis University, Cairo, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. The present study aims to investigate the novel efficacy of both insulin and vitamin E against fatty liver induced rats. Rats were divided into three groups: control, fatty liver induced, and fatty liver induced treated group received insulin and vitamin E for ten days. The data revealed a decrease in lipid profile in the treated group in comparison with fatty liver group, also a significant decrease in weight was observed in the treated group compared with the fatty liver group, in addition to a slight improvement in the albumin in the treated group. In conclusion, a combination between both vitamin E and insulin may be useful for ameliorating lipid profile and decreasing the body weight in the fatty liver rats.

  1. Albanis, E.; Friedman, S.L. Antifibrotic agents for liver disease. J. Transplant. 2006, 6, 12?19.
  2. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142, 1592?1609.
  3. Elaroussi,M.A., Fattah,M.A., Meky, N.H., Ezzat,I.E. and Wakwak, M.M. Effects of vitamin E,age and sex on performance of Japanese quil.1. Hematological indices and liver function. Poult. Sci 2007, 48(6):669-677.
  4. Elsayed A, ElGebely S, Galal A. Insulin therapy induced adiposity evaluated by computed tomography is no visceral. Pak J Med Sci. 2007; 23(2):161?166.
  5. Fabbrini, E.; Magkos, F.; Mohammed, B.S.; Pietka, T.; Abumrad, N.A.; Patterson, B.W.; Okunade, A.; Klein, S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Natl. Acad. Sci. USA 2009, 106, 15430?15435.
  6. Gastaldelli, A.; Cusi, K.; Pettiti, M.; Hardies, J.; Miyazaki, Y.; Berria, R.; Buzzigoli, E.; Sironi, A.M.; Cersosimo, E.; Ferrannini, E.; et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007, 133, 496?506.
  7. Jimba, S.; Nakagami, T.; Takahashi, M.; Wakamatsu, T.; Hirota, Y.; Iwamoto, Y.; Wasada, T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Med. 2005, 22, 1141?1145.
  8. Kammoun, H.L.; Chabanon, H.; Hainault, I.; Luquet, S.; Magnan, C.; Koike, T.; Ferre, P.; Foufelle, F. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. Clin. Investig.2009, 119, 1201?1215.
  9. Kang YH, Min HK, Son SM, Kim IJ and Kim YK. The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res ClinPract 2007, 77:306?313
  10. Kim CH, Park JY, Lee KU, Kim JH,and Kim HK. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 2009, 25:64?69.
  11. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Jrvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J PhysiolEndocrinolMetab. 2007; 292(3): E829?35. [PubMed: 17090752]
  12. Lee DH and Jacobs DR. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005, 178:327?330.
  13. Lee MY, Koh SB, Koh JH, Nam SM, Shin JY, Shin YG,Kong ID, Ryu SY, Park JK, and Chung CH. Relationship between gamma-glutamyltransferase and metabolic syndrome in a Korean population. DiabetMed 2008, 25:469?475.
  14. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A,Hardies J, Dar?land C, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with NAFLD. Hepatology 2012; 55: 1389-1397.
  15. Massiera F, Barbry P, Guesnet P, Joly A, Luquet S, Moreilhon-Brest C, Mohsen-Kanson T, Amri EZ, and Ailhaud G. A Western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations. J Lipid Res. 2010 ,51:2352?61.
  16. Pruthi, S., Allison, T. and hensrud, D. Vitamin E supplementation in the prevention of coronary heart diseases. Mayo Clin. Proc 2001, 76(11):1131-1136.
  17. Ryysy, L.; Hakkinen, A.M.; Goto, T.; Vehkavaara, S.; Westerbacka, J.; Halavaara, J.; Yki-Jarvinen, H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000, 49, 749?758.
  18. Smith, B.W.; Adams, L.A. Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment. Rev. Endocrinol. 2011, 7, 456?465.
  19. Stefan, N.; Kantartzis, K.; Machann, J.; Schick, F.; Thamer, C.; Rittig, K.; Balletshofer, B.; Machicao, F.; Fritsche, A.; Haring, H.U. Identification and characterization of metabolically benign obesity in humans. Intern. Med. 2008, 168, 1609?1616.
  20. Van Wagner, L.B.; Rinella, M.E.The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Adv. Gastroenterol. 2011, 4, 249?263.
  21. Williamson, R.M.; Price, J.F.; Glancy, S.; Perry, E.; Nee, L.D.; Hayes, P.C.; Frier, B.M.; van Look, L.A.; Johnston, G.I.; Reynolds, R.M.; et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care 2011, 34, 1139?1144.
  22. Zoppini, G.; Targher, G.; Trombetta, M.; Lippi, G.; Muggeo, M. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. Obesity 2009, 17, 370?374.

[Ingy Badawy, Mahmoud Mohsen, Alaa Ahmed, Shrouk Mahmoud, Amany Saeed, Amr Atef, Al-Taher Rabea, Marina Maurice and Baher Zlat. (2018); NOVEL THERAPEUTIC USE OF INSULIN AND VITAMIN E IN (NAFLD) USING FATTY LIVER INDUCED RATS. Int. J. of Adv. Res. 6 (May). 927-931] (ISSN 2320-5407). www.journalijar.com

Baher Zlat
1 Faculty of Biotechnology, Misr University for Science and Technology, Giza, Egypt

DOI:

Article DOI: 10.21474/IJAR01/7113      
DOI URL: https://dx.doi.org/10.21474/IJAR01/7113

Download Full Paper

Download PDF No. of Downloads: 34 | No. of Views: 114